Message #16 From:
Stock News Bot Date: August 31, 2006 11:58:00 AM
ISRY News IsoRay Inc. to Present at Roth Capital Conference in New York on September 7
NEW YORK--(BUSINESS WIRE)--Aug. 31, 2006--IsoRay Inc, ("IsoRay") (OTCBB:ISRY), a medical technology company focusing on innovative treatment for prostate and other soft tissue cancer tumors through the use of its proprietary Cesium-131, announces that management will present at the Roth Capital Partners New York Conference on September 7, 2006 at the Westin Time Square Hotel in New York, NY.
The company roster will include a scheduled presentation at 2:30 p.m. Eastern and will also be accessible to the public as a web cast during the presentation. To monitor the presentation live, please connect to the following link up to 15 minutes prior to the commencement of the presentation: http://www.wsw.com/webcast/roth8/isry.ob/
The presentation will also be available for a limited period of time following the conference.
Management will also be available to conduct individual meetings at the conference and in the Midtown New York area. Institutional investors interested in meeting with management should contact Roth Capital Partners regarding conference meetings or Ralph Schatzmair, who will be named V.P. Investor Relations for IsoRay Inc, after consulting to IsoRay over the last year, at 416-624-4102 for meetings outside the conference schedule.
Information regarding the conference can be found online at www.rothconference.com. The Roth Conference is available by invitation of Roth Capital Partners only.
About IsoRay
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is the sole producer of the Cesium-131 brachytherapy seed (www.cesium131.com), used to treat prostate and other cancers. The Cesium-131 seed offers a significantly shorter half-life than the two other isotopes commonly used for brachytherapy, which results in a substantially faster delivery of therapeutic radiation, lower probability of cancer cell survival and reduction of the longevity of common brachytherapy side effects. IsoRay is based in Richland, Washington. More information is available about IsoRay at www.isoray.com.
IsoRay Medical, Inc., 350 Hills Street, Suite 106, Richland, WA 99352, 1-877-4-ISORAY, 509-375-1202, 509-375-3473 (FAX)
